CN115315432A - 亲环蛋白抑制剂及其用途 - Google Patents

亲环蛋白抑制剂及其用途 Download PDF

Info

Publication number
CN115315432A
CN115315432A CN202180023173.3A CN202180023173A CN115315432A CN 115315432 A CN115315432 A CN 115315432A CN 202180023173 A CN202180023173 A CN 202180023173A CN 115315432 A CN115315432 A CN 115315432A
Authority
CN
China
Prior art keywords
compound
organ
pharmaceutically acceptable
donor
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023173.3A
Other languages
English (en)
Chinese (zh)
Inventor
麦靖邦
H·弗莱里
马法书
M·皮尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruinuo Medical Technology Shanghai Co ltd
Original Assignee
Ruinuo Medical Technology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruinuo Medical Technology Shanghai Co ltd filed Critical Ruinuo Medical Technology Shanghai Co ltd
Publication of CN115315432A publication Critical patent/CN115315432A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180023173.3A 2020-03-26 2021-03-25 亲环蛋白抑制剂及其用途 Pending CN115315432A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020081296 2020-03-26
CNPCT/CN2020/081296 2020-03-26
PCT/CN2021/083015 WO2021190603A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN115315432A true CN115315432A (zh) 2022-11-08

Family

ID=77891508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023173.3A Pending CN115315432A (zh) 2020-03-26 2021-03-25 亲环蛋白抑制剂及其用途

Country Status (9)

Country Link
US (1) US20230203099A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126903A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023518775A (cg-RX-API-DMAC7.html)
KR (1) KR20220158759A (cg-RX-API-DMAC7.html)
CN (1) CN115315432A (cg-RX-API-DMAC7.html)
AU (1) AU2021244763A1 (cg-RX-API-DMAC7.html)
CA (1) CA3172689A1 (cg-RX-API-DMAC7.html)
TW (1) TW202144378A (cg-RX-API-DMAC7.html)
WO (1) WO2021190603A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113329626A (zh) * 2019-01-20 2021-08-31 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN115028679B (zh) * 2022-08-11 2022-11-15 深圳湾实验室 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
CA2518265A1 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
MX2011001152A (es) * 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
AU2011342284C1 (en) * 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
AU2017267560B2 (en) * 2016-05-17 2022-03-24 S&T Global Inc. Novel cyclosporin derivatives and uses thereof
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
CN116870135A (zh) * 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113329626A (zh) * 2019-01-20 2021-08-31 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途

Also Published As

Publication number Publication date
AU2021244763A1 (en) 2022-10-06
EP4126903A1 (en) 2023-02-08
CA3172689A1 (en) 2021-09-30
KR20220158759A (ko) 2022-12-01
EP4126903A4 (en) 2024-05-08
US20230203099A1 (en) 2023-06-29
TW202144378A (zh) 2021-12-01
JP2023518775A (ja) 2023-05-08
WO2021190603A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
JP7776435B2 (ja) シクロフィリン阻害剤およびその使用
TW202144378A (zh) 親環蛋白抑制劑及其用途
JP7839090B2 (ja) ネフロトキシン誘発性腎障害の処置及び予防
JP2017523178A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤
KR20160110399A (ko) 메갈린 길항제
KR20050119104A (ko) 치환된 퀴놀린과 치환된 디페닐설폰을 함유하는 조성물과방법
US12318368B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
EA051978B1 (ru) Ингибиторы циклофилина и их применение
US12435074B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
US12398128B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
US12297175B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
US12384746B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
EP1391203A1 (en) Antitumor agents
KR20060066176A (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 신기능 치료제 조성물
EP2908820A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
US20040152772A1 (en) 1-butyric acid derivatives and the use thereof
EP2601963A1 (en) N-isovaleroyl-l-glutamyl-l-tryptophan as an agent inhibiting the formation of ulcers in the stomach and the duodenum

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination